Kallyope’s Phase 2b Study of Elismetrep, A Novel Approach for Treating Migraine, Presented at the American Academy of Neurology Annual Meeting Portfolio News / By Libby Nunan Kallyope’s Phase 2b Study of Elismetrep, A Novel Approach for Treating Migraine, Presented at the American Academy of Neurology Annual Meeting Read More »
Neurona Presents Updated Data from Ongoing Clinical Trials of Rezanecel (NRTX 1001) Regenerative Cell Therapy in Mesial Temporal Lobe Epilepsy at 2026 American Academy of Neurology (AAN) Annual Meeting Portfolio News / By Libby Nunan Neurona Presents Updated Data from Ongoing Clinical Trials of Rezanecel (NRTX 1001) Regenerative Cell Therapy in Mesial Temporal Lobe Epilepsy at 2026 American Academy of Neurology (AAN) Annual Meeting Read More »
A2 Biotherapeutics to Highlight Progress of CAR T-Cell Clinical Programs in Three Poster Presentations During the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Portfolio News / By Libby Nunan A2 Biotherapeutics to Highlight Progress of CAR T-Cell Clinical Programs in Three Poster Presentations During the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Read More »
Tortugas Neuroscience Launches with $106 Million to Advance Clinical Stage Pipeline Targeting New and Major Neurology and Neuropsychiatric Disorders Portfolio News / By Libby Nunan Tortugas Neuroscience Launches with $106 Million to Advance Clinical Stage Pipeline Targeting New and Major Neurology and Neuropsychiatric Disorders Read More »
Synthekine Presents Updated Clinical and Translational Data Demonstrating Strong Activity for STK-012 in First-Line Non-Squamous NSCLC in Oral Presentation at AACR 2026 Portfolio News / By Libby Nunan Synthekine Presents Updated Clinical and Translational Data Demonstrating Strong Activity for STK-012 in First-Line Non-Squamous NSCLC in Oral Presentation at AACR 2026 Read More »
Remix Therapeutics™ Announces Oral Presentation of First-in-Class Small Molecule MYB mRNA Degrader REM-422 Phase 1/2 ARIA Trial Results at the 2026 American Society of Clinical Oncology Annual Meeting Portfolio News / By Libby Nunan Remix Therapeutics™ Announces Oral Presentation of First-in-Class Small Molecule MYB mRNA Degrader REM-422 Phase 1/2 ARIA Trial Results at the 2026 American Society of Clinical Oncology Annual Meeting Read More »
Neurona Therapeutics to Be Acquired by UCB Portfolio News / By Libby Nunan Neurona Therapeutics to Be Acquired by UCB Read More »
Accent Therapeutics Presents Data Reinforcing Therapeutic Potential of Novel KIF18A Inhibitor, ATX-295, at the 2026 American Association for Cancer Research Annual Meeting Portfolio News / By Libby Nunan Accent Therapeutics Presents Data Reinforcing Therapeutic Potential of Novel KIF18A Inhibitor, ATX-295, at the 2026 American Association for Cancer Research Annual Meeting Read More »
Accent Therapeutics to Present Preclinical Data on Lead Clinical Program, ATX-295, at the 2026 American Association for Cancer Research Annual Meeting Portfolio News / By Libby Nunan Accent Therapeutics to Present Preclinical Data on Lead Clinical Program, ATX-295, at the 2026 American Association for Cancer Research Annual Meeting Read More »
A2 Biotherapeutics Receives U.S. FDA Fast Track Designation for A2B543, a Logic-Gated CAR T-Cell Therapy Enhanced with a Membrane-Tethered IL-12 Booster Portfolio News / By Libby Nunan A2 Biotherapeutics Receives U.S. FDA Fast Track Designation for A2B543, a Logic-Gated CAR T-Cell Therapy Enhanced with a Membrane-Tethered IL-12 Booster Read More »
